- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis
Drug guidance
Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis
Condition
Musculoskeletal
Skin
3 May 2017
Published on 03 May 2017
Last Updated on 03 May 2017
Guidance Recommendation
The Ministry of Health’s Drug Advisory Committee has not recommended ustekinumab to be listed on the Medication Assistance Fund (MAF) for the treatment of chronic plaque psoriasis and psoriatic arthritis.